The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 05, 2018
Filed:
Feb. 17, 2017
Fujifilm Corporation, Tokyo, JP;
Tomoki Naoe, Nagoya, JP;
Hitoshi Kiyoi, Nagoya, JP;
Shinji Hagiwara, Ashigarakami-gun, JP;
Masaru Takasaki, Ashigarakami-gun, JP;
Daisuke Hirano, Ashigarakami-gun, JP;
Toshiyuki Nakatani, Ashigarakami-gun, JP;
Takeshi Yamaura, Ashigarakami-gun, JP;
FUJIFILM Corporation, Tokyo, JP;
Abstract
Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation.